Incyte begins Phase III clinical trial for vitiligo drug in China
What happened
Incyte is conducting a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study in Shenzhen, China. The trial evaluates the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. The study is planned for approximately 44 clinical research centers across China and aims to enroll about 174 patients. The drug has previously been certified as a Breakthrough Therapeutic Drug by the National Medical Products Administration of the People’s Republic of China.
From briefingwire.com
Why it matters
The enrollment of the first patient marks a key stage in the drug’s clinical evaluation in China. The Breakthrough Therapeutic Drug certification from the National Medical Products Administration of the People’s Republic of China may accelerate the drug's development and review process, potentially aiding market access.
From briefingwire.com